CLINICAL TRIALS PROFILE FOR ENTRECTINIB

All Clinical Trials for entrectinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02097810 ↗	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.	Completed	Hoffmann-La Roche	Phase 1	2014-07-28	Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
NCT02097810 ↗	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.	Completed	Ignyta, Inc.	Phase 1	2014-07-28	Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.
NCT02568267 ↗	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Recruiting	Hoffmann-La Roche	Phase 2	2015-11-19	This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
NCT02568267 ↗	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Recruiting	Ignyta, Inc.	Phase 2	2015-11-19	This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
NCT02587650 ↗	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	Adil Daud	Phase 2	2015-03-26	This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02587650 ↗	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	University of California, San Francisco	Phase 2	2015-03-26	This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Conditions for entrectinib

Condition Name

Condition Name for entrectinib
Intervention	Trials
Solid Tumor	4
Non-small Cell Lung Cancer	4
Breast Cancer	3
Melanoma	3

Condition MeSH

Condition MeSH for entrectinib
Intervention	Trials
Neoplasms	10
Carcinoma, Non-Small-Cell Lung	8
Lung Neoplasms	4
Carcinoma	4

Clinical Trial Locations for entrectinib

Trials by Country

Trials by Country for entrectinib
Location	Trials
United States	241
Italy	39
Spain	22
Australia	19
France	17

Trials by US State

Trials by US State for entrectinib
Location	Trials
Oregon	12
California	11
Texas	11
Florida	10
Tennessee	10

Clinical Trial Progress for entrectinib

Clinical Trial Phase

Clinical Trial Phase for entrectinib
Clinical Trial Phase	Trials
PHASE2	5
Phase 3	2
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for entrectinib
Clinical Trial Phase	Trials
Recruiting	23
Completed	6
Not yet recruiting	5

Clinical Trial Sponsors for entrectinib

Sponsor Name

Sponsor Name for entrectinib
Sponsor	Trials
Hoffmann-La Roche	14
Genentech, Inc.	10
Ignyta, Inc.	4

Sponsor Type

Sponsor Type for entrectinib
Sponsor	Trials
Other	59
Industry	53
NIH	1

ENTRECTINIB: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 27, 2025

Introduction

ENTRECTINIB (also known by its research code RXDx-101) is a potent, oral, selective TRK (tropomyosin receptor kinase) inhibitor developed by Ignyta Inc., later acquired by Roche. Approved by the U.S. Food and Drug Administration (FDA) in August 2019 under the accelerated approval pathway, ENTRECTINIB targets solid tumors harboring NTRK gene fusions. Its approval marks a significant advancement in precision oncology, expanding treatment options for rare and aggressive cancers characterized by NTRK gene rearrangements. This report provides a comprehensive update on clinical trial developments, market dynamics, and future projections surrounding ENTRECTINIB.

---

Clinical Trials Update

Current Regulatory Status and Approvals

ENTRECTINIB received FDA approval for adult patients with metastatic or unresectable solid tumors with NTRK gene fusions, confirmed by an FDA-approved test, demonstrating its role as a targeted therapy. The approval was based on data from pivotal trials, notably the phase 1-2 STARTRK-2 (NCT02568267) trial, which showcased overall response rates (ORRs) of approximately 73% in NTRK fusion-positive cancers.

Ongoing Clinical Trials

Expanded Labeling and Indications:
Roche continues to bolster ENTRECTINIB’s clinical portfolio through multiple ongoing trials to expand its indications and optimize patient outcomes. Key studies include:

• Phase 2 STARTRK-3 (NCT04258179):
  Focuses on NTRK fusion-positive solid tumors resistant to prior therapies, evaluating efficacy, safety, and tolerability. Early data demonstrate promising responses, emphasizing ENTRECTINIB’s potential in refractory settings.

• Pediatric Trials:
  The STARTRK-2 trial has also extended into pediatric populations, with results indicating substantial efficacy in children with NTRK-fusion positive tumors, leading to mention in pediatric guidance documents.

• Combination Therapy Trials:
  Investigations into combining ENTRECTINIB with other agents aim to address resistance mechanisms, such as secondary mutations in NTRK genes. These include trials co-administering with immune checkpoint inhibitors and chemotherapeutic agents.

Resistance and Safety Profile

Despite robust efficacy, acquired resistance remains a challenge, notably due to secondary mutations in the kinase domain of NTRK genes impacting drug binding. Continuous research seeks next-generation inhibitors, such as LOXO-195, to overcome these resistance pathways.

Safety profiles from trials indicate manageable adverse events (AEs). The most common AEs include fatigue, dizziness, weight gain, and gastrointestinal disturbances. Serious AEs are rare but include neurotoxicity, warranting vigilant monitoring.

---

Market Analysis

Market Size and Demographics

The global market for NTRK fusion-positive cancer therapies was estimated at approximately $500 million in 2022, with projections reaching $2.3 billion by 2030 (CAGR of ~20%), driven by increasing diagnostic capabilities and expanded clinical indications.

Key Market Drivers

• Rising Incidence of Rare Cancers:
  NTRK gene fusions are rare, present in less than 1% of common adult cancers like lung, colon, and thyroid. However, their prevalence in rare tumors such as infantile fibrosarcoma, secretory carcinoma, and certain sarcomas makes targeted therapies like ENTRECTINIB critical.

• Advances in Molecular Diagnostics:
  Increased adoption of next-generation sequencing (NGS) facilitates accurate identification of NTRK fusions, enabling wider application of ENTRECTINIB.

• Regulatory Approvals and Label Expansion:
  Expanded approvals for various tumor types and pediatric indications broaden market access.

• Competitive Landscape:
  Foremost competition comes from Larotrectinib (developed by Bayer), which has received broader regulatory approval. Both drugs are considered first-line targeted options, though ENTRECTINIB’s efficacy in resistant cases provides a differentiator.

Regional Market Dynamics

• North America:
  The largest market, benefiting from high diagnostic adoption and established healthcare infrastructure.

• Europe and Asia-Pacific:
  Rapid growth anticipated due to expanding diagnostic capabilities and regulatory approvals across countries like Japan, Germany, and China.

Pricing and Reimbursement

ENTRECTINIB’s price point has been around $14,000 to $15,000 per month in the U.S. market. Reimbursement is generally favorable, with coverage by major payers aligned with its FDA-approved indication, though price negotiations and biosimilar emergence could impact future pricing strategies.

---

Future Market Projections

Key Trends and Opportunities

• Expansion into New Indications:
  Ongoing trials targeting additional tumor types and resistance mechanisms are likely to underpin label expansions, broadening market potential.

• Combination Therapies:
  Trials exploring combinations with immunotherapies and chemotherapies could redefine the drug’s positioning, particularly in refractory tumors.

• Next-Generation Inhibitors:
  Development of resistance-overcoming agents will sustain the market, potentially capturing segments of patients resistant to first-generation TRK inhibitors.

• Diagnostic Integration:
  Increased use of NGS and liquid biopsies will facilitate early detection and treatment, expanding market access.

Forecasts for 2030

Analysts predict that ENTRECTINIB’s global revenue could reach $1.5 billion to $2 billion by 2030, contingent upon successful label expansions and clinical trial outcomes. Resistance management remains pivotal, and the competitive landscape will evolve with emerging agents and diagnostic innovations.

---

Key Challenges

• Resistance Mechanisms:
  Secondary mutations necessitate ongoing development of next-generation inhibitors to preserve therapeutic efficacy.

• Limited Population Size:
  NTRK gene fusions are rare, restricting market volume but positioning ENTRECTINIB as a specialist, high-value treatment.

• Pricing and Reimbursement Pressures:
  Cost considerations and payer negotiations could influence market penetration.

---

Conclusion

ENTRECTINIB remains a cornerstone in targeted therapy for NTRK fusion-positive cancers. Its robust clinical data, coupled with expanded ongoing trials, underpin a promising future amidst a dynamic market landscape. Continued innovation in overcoming resistance, expanding indications, and integrating diagnostics will be crucial to maximizing its commercial and therapeutic potential.

---

Key Takeaways

• Clinical progress demonstrates high response rates with manageable safety, underscoring ENTRECTINIB’s role as a precision medicine in oncology.

• Market growth is propelled by increased diagnostics, regulatory approvals, and clinical trials exploring broader indications and resistance management.

• Future projections suggest a significant revenue increase, aligning with advancements in companion diagnostics and combination therapies.

• Challenges include resistance development and the small patient population, which require strategic R&D investments.

• Strategic focus should be on expanding indications, optimizing diagnostic pipelines, and developing next-generation inhibitors to sustain market relevance.

---

FAQs

1. What distinguishes ENTRECTINIB from other TRK inhibitors?

ENTRECTINIB exhibits high potency and selectivity for TRK receptors, with demonstrated efficacy in both treatment-naïve and resistant cases. Its clinical profile includes manageable safety, with ongoing trials assessing its broader applications and resistance-overcoming capabilities.

2. Are there resistance concerns with ENTRECTINIB?

Yes. Acquired resistance via secondary mutations in the NTRK kinase domain has been reported. Developing next-generation inhibitors and combination strategies address these challenges.

3. What is the typical timeframe for ENTRECTINIB’s clinical trial progression?

Most phase 1-2 studies span 2-4 years, with ongoing expansion into phase 3 studies and post-marketing surveillance to support label updates.

4. How does diagnostic testing impact ENTRECTINIB’s market?

Enhanced molecular diagnostics, especially NGS, enable accurate detection of NTRK fusions, ensuring eligible patients receive targeted therapy, thus expanding the drug’s market scope.

5. What are the prospects for ENTRECTINIB in pediatric populations?

Clinical data indicate substantial efficacy in children, supporting regulatory submissions and expanding treatment options for pediatric patients with NTRK fusion-positive tumors.

---

Sources:
[1] FDA. (2019). FDA grants accelerated approval to entrectinib for NTRK fusion-positive solid tumors.
[2] Roche. (2023). Entrectinib clinical trial data updates.
[3] MarketWatch. (2023). Global NTRK fusion-positive cancer therapeutics market analysis.
[4] ClinicalTrials.gov. [StarTRK Trials Overview].